CADL

Candel Therapeutics, Inc.

Healthcare
Biotechnology
$773M market cap

Forecast run · Sep 14, 2026Upside rank 419 of 3,136

Model Signal

ForecastQ Daily Probabilities

57.8%

41.2%

47.4%

Analyst Consensus

Recommendation2.10/5 Buy

Last price$10.55

Price target$22.50

Implied move+113.4%

Analysts10

ForecastQ Portfolios

CADL is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade glioma. Furthermore, the company is advancing CAN-3110, an investigational therapy currently in Phase I clinical trials for recurrent glioblastoma. Established in 2003, the company operated as Advantagene, Inc. until November 2020, when it rebranded as Candel Therapeutics, Inc.